^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer.
Published date:
05/25/2023
Excerpt:
Among LTR compared to patients with best response of PD, dNLR < 3.0 (OR 1.72, p = 0.030), high PD-L1 (OR 5.23, p < 0.001), and high TMB (OR 2.55, p = 0.001) associated with LTR.
DOI:
10.1200/JCO.2023.41.16_suppl.9107
Source:
Title:
The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
Published date:
11/13/2021
Excerpt:
A total of 2338 patients with advanced or metastatic NSCLC from six randomized controlled trials, which all used chemotherapy (CT) as a control, were included in this study….Patients with high bTMB tend to obtain significantly better OS, PFS, and ORR from PD-1/PD-L1 inhibitor therapy than from CT.
DOI:
10.1186/s12885-021-08924-z
Source:
Title:
A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy
Published date:
11/25/2020
Excerpt:
All patients received blockade immunotherapy [either anti-cytotoxic T lymphocyte-associated antigen (CTLA-4) or anti-PD-1]....In validation data, HW-TMB was associated with survival (p = 0.0057) and predicted 6-month clinical benefit (AUROC = 0.83) in NSCLC.
DOI:
10.1038/s41598-020-77653-3
Source:
Title:
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
Published date:
08/03/2020
Excerpt:
...The associations of these biomarkers with the therapeutic effect of PD-1 inhibitor were analysed in a cohort of NSCLC samples...Patients in the CR/PR group (anti-PD-1 therapy) had higher levels of PD-L1 expression, TMB, PD-1+ Tils, and CD8+ T cell infiltration, and many patients in this group exhibited concomitantly elevated levels of multiple biomarkers...
DOI:
10.1186/s40164-020-00173-3
Source:
Title:
Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Excerpt:
We confirmed that high TMB was associated with improved clinical outcomes, and TMB quantified by gene panel strongly correlated with WES results (Spearman's ρ = 0.81)....Based on WES-assessed TMB results, DCB rate and mPFS were both significantly increased in patients with high TMB (top 33%, cutoff = 157 mutations; DCB rate, 44.0% vs. 18.8%, Fisher's exact test P = 0.03; mPFS, 130 vs. 60.5 days, log rank P = 0.0018, HR, 0.43; 95% confidence interval (CI), 0.25–0.74...In addition, patients with high TMB assessed by both methods had a trend toward increased ORR rate (WES, 28.0% vs. 14.6%, Fisher's exact test P = 0.21; Panel, 26.9% vs. 14.3%, Fisher's exact test P = 0.22...
DOI:
10.1158/1078-0432.CCR-19-0585
